AgomAb Therapeutics agomab.com


AgomAb Therapeutics aims to develop a pipeline of growth factor-mimetic agonistic monoclonal antibodies (agomAbs) with applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases, with the HGF mimetic as lead.

AgomAb Therapeutics aims to develop a pipeline of growth factor-mimetic agonistic monoclonal antibodies (agomAbs) with applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases, with the HGF mimetic as lead.

Company (Alive / Active)

Phone:

Fax:

Pieter Van Reysschootlaan 2/104

Sint-Denijs-Westrem, 9051
Belgium

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
AgomAb Therapeutics $23.6M Apr 3, 2019

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related AgomAb Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Omnes CapitalPrivate EquityParis, FranceSeries A
PontifaxVenture CapitalHerzliya, IsraelSeries A
Boehringer Ingelheim Venture FundCorporate VentureIngelheim am Rhein, GermanySeries A
V-Bio VenturesVenture CapitalGent, BelgiumSeries A
Advent France BiotechnologyVenture CapitalParis, FranceSeries A
See all 5 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)